JP5931442B2 - 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 - Google Patents

操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 Download PDF

Info

Publication number
JP5931442B2
JP5931442B2 JP2011525134A JP2011525134A JP5931442B2 JP 5931442 B2 JP5931442 B2 JP 5931442B2 JP 2011525134 A JP2011525134 A JP 2011525134A JP 2011525134 A JP2011525134 A JP 2011525134A JP 5931442 B2 JP5931442 B2 JP 5931442B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011525134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501332A5 (https=
JP2012501332A (ja
Inventor
シューホン リー，
シューホン リー，
ラメッシュ エス． カシ，
ラメッシュ エス． カシ，
アニーケット バドカー，
アニーケット バドカー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2012501332A publication Critical patent/JP2012501332A/ja
Publication of JP2012501332A5 publication Critical patent/JP2012501332A5/ja
Application granted granted Critical
Publication of JP5931442B2 publication Critical patent/JP5931442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
JP2011525134A 2008-08-27 2009-08-25 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 Active JP5931442B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9232608P 2008-08-27 2008-08-27
US61/092,326 2008-08-27
PCT/US2009/054842 WO2010027766A1 (en) 2008-08-27 2009-08-25 Lyophilized formulatons of engineered anti-il-23p19 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015184258A Division JP2016028086A (ja) 2008-08-27 2015-09-17 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2012501332A JP2012501332A (ja) 2012-01-19
JP2012501332A5 JP2012501332A5 (https=) 2012-10-04
JP5931442B2 true JP5931442B2 (ja) 2016-06-08

Family

ID=41495339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011525134A Active JP5931442B2 (ja) 2008-08-27 2009-08-25 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
JP2015184258A Pending JP2016028086A (ja) 2008-08-27 2015-09-17 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015184258A Pending JP2016028086A (ja) 2008-08-27 2015-09-17 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤

Country Status (8)

Country Link
US (1) US8263748B2 (https=)
EP (1) EP2331078B1 (https=)
JP (2) JP5931442B2 (https=)
CN (1) CN102202655B (https=)
AU (1) AU2009288419B2 (https=)
CA (1) CA2734919C (https=)
MX (1) MX2011002159A (https=)
WO (1) WO2010027766A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2596022A4 (en) * 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
EP2798077A2 (en) 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
EP4039275A1 (en) * 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
CZ304514B6 (cs) 2012-11-23 2014-06-11 Biotechnologický Ústav Av Čr, V.V.I. Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
EP2968488A1 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
HRP20200399T1 (hr) 2016-01-22 2020-06-12 Baxter International Inc. Postupak i stroj za proizvodnju vrećica za sterilne otopine
PT3405161T (pt) 2016-01-22 2020-01-29 Baxter Healthcare Sa Saco de produto para soluções estéreis
US10940185B2 (en) 2016-12-28 2021-03-09 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3105598A1 (en) 2018-07-13 2020-01-16 Carl GOMMOLL Treating ulcerative colitis with brazikumab
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
EP3904382A4 (en) 2018-11-27 2022-07-13 Innovent Biologics (Suzhou) Co., Ltd. ANTI-IL-23P19 ANTIBODIES AND ITS USES
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2020212874A1 (en) * 2019-04-15 2020-10-22 Sun Pharma Global Fze Methods for treatment of subjects with psoriatic arthritis
US12577297B2 (en) * 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
GB202107153D0 (en) * 2021-05-19 2021-06-30 UCB Biopharma SRL Method for filling vials containing liquid drug products
CN115785267B (zh) * 2021-09-10 2023-12-15 三优生物医药(上海)有限公司 一种靶向IL-23p19的抗体或其抗原结合片段及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
KR101424624B1 (ko) * 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
WO2005035574A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
KR20080019249A (ko) 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
SI1971366T1 (sl) * 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
CA2644906C (en) * 2006-03-06 2016-05-10 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos

Also Published As

Publication number Publication date
AU2009288419A1 (en) 2010-03-11
WO2010027766A1 (en) 2010-03-11
JP2016028086A (ja) 2016-02-25
EP2331078A1 (en) 2011-06-15
US20110229490A1 (en) 2011-09-22
EP2331078B1 (en) 2012-09-19
CA2734919A1 (en) 2010-03-11
JP2012501332A (ja) 2012-01-19
CA2734919C (en) 2016-08-16
US8263748B2 (en) 2012-09-11
MX2011002159A (es) 2011-03-29
CN102202655B (zh) 2013-06-19
AU2009288419B2 (en) 2015-08-06
CN102202655A (zh) 2011-09-28

Similar Documents

Publication Publication Date Title
JP5931442B2 (ja) 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
US20240239884A1 (en) SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
CN111315411B (zh) 高浓度抗c5抗体制剂
CN109078182B (zh) 抗体制剂
MX2014013434A (es) Formulaciones liofilizadas y acuosas de anticuerpo anti-cd40.
US20190010224A1 (en) Formulations of engineered anti-il-10 antibodies
CN113194925B (zh) 抗体制剂
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
US20240025978A1 (en) Methods for treating complement-mediated diseases
EP3939611A1 (en) Pharmaceutical composition containing antibody against il-5 and use thereof
JP2026503045A (ja) Ｔｓｌｐ抗体を使用して喘息を治療するための方法
HK40000750B (en) Antibody formulations
HK40000750A (en) Antibody formulations
HK1261758A1 (en) Antibody formulations
HK1215194B (en) Solution formulations of engineered anti-il-23p19 antibodies
HK1218128B (zh) 改善药代动力学的具有跨ph范围差异结合的抗tfpi抗体变体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140130

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160427

R150 Certificate of patent or registration of utility model

Ref document number: 5931442

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250